Abeona Therapeutics Inc (NASDAQ:ABEO – Get Rating) – Research analysts at Cantor Fitzgerald upped their FY2023 earnings per share estimates for Abeona Therapeutics in a research note issued on Tuesday, November 15th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biopharmaceutical company will earn ($1.92) per share for the year, up from their prior estimate of ($2.41). Cantor Fitzgerald currently has a “Overweight” rating and a $40.00 target price on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($4.00) per share.
A number of other research analysts also recently weighed in on the company. Alliance Global Partners started coverage on Abeona Therapeutics in a report on Thursday, September 15th. They issued a “buy” rating on the stock. StockNews.com raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Abeona Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $55.00.
Abeona Therapeutics Price Performance
Hedge Funds Weigh In On Abeona Therapeutics
Several institutional investors have recently added to or reduced their stakes in ABEO. AIGH Capital Management LLC grew its holdings in Abeona Therapeutics by 341.9% during the 1st quarter. AIGH Capital Management LLC now owns 5,025,100 shares of the biopharmaceutical company’s stock valued at $1,583,000 after buying an additional 3,887,826 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Abeona Therapeutics by 6.8% during the 1st quarter. Renaissance Technologies LLC now owns 2,325,816 shares of the biopharmaceutical company’s stock valued at $733,000 after buying an additional 148,200 shares in the last quarter. Worth Venture Partners LLC grew its holdings in Abeona Therapeutics by 9.5% during the 1st quarter. Worth Venture Partners LLC now owns 1,244,774 shares of the biopharmaceutical company’s stock valued at $392,000 after buying an additional 107,500 shares in the last quarter. Citigroup Inc. purchased a new position in Abeona Therapeutics during the 1st quarter valued at approximately $27,000. Finally, BlackRock Inc. boosted its holdings in shares of Abeona Therapeutics by 4.7% in the 1st quarter. BlackRock Inc. now owns 1,694,624 shares of the biopharmaceutical company’s stock worth $534,000 after purchasing an additional 76,694 shares during the period.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
- Get a free copy of the StockNews.com research report on Abeona Therapeutics (ABEO)
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ’s Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.